HALO.NASDAQHalozyme Therapeutics, INC
Form 4: Halozyme Therapeutics CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Helen Torley, PRESIDENT AND CEO and a Director of Halozyme Therapeutics, Inc., sold 60,000 shares of common stock on October 6, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on October 6, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 2,300 Common Stock at $107.90 ($248,175) on October 6, 2026; holds 785,480 after (Direct).
- Open-market sale: disposed of 6,000 Common Stock at $109.33 ($656,004) on October 6, 2026; holds 779,480 after (Direct).
- Open-market sale: disposed of 9,920 Common Stock at $109.89 ($1,090,119) on October 6, 2026; holds 769,560 after (Direct).
- Open-market sale: disposed of 1,780 Common Stock at $110.81 ($197,245) on October 6, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on October 7, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 8,600 Common Stock at $111.03 ($954,867) on October 7, 2026; holds 779,180 after (Direct).
- Open-market sale: disposed of 10,300 Common Stock at $111.84 ($1,151,942) on October 7, 2026; holds 768,880 after (Direct).
- Open-market sale: disposed of 900 Common Stock at $112.78 ($101,502) on October 7, 2026; holds 767,980 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $113.69 ($22,739) on October 7, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on October 8, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 4,810 Common Stock at $108.18 ($520,341) on October 8, 2026; holds 782,970 after (Direct).
- Open-market sale: disposed of 3,090 Common Stock at $108.91 ($336,526) on October 8, 2026; holds 779,880 after (Direct).
- Open-market sale: disposed of 11,900 Common Stock at $110.00 ($1,308,940) on October 8, 2026; holds 767,980 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $110.51 ($22,102) on October 8, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on October 6, 2026; holds 61,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on October 7, 2026; holds 41,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on October 8, 2026; holds 21,552 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,610,501 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Helen Torley — Director, Officer (PRESIDENT AND CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-10-06 | Open-market sale | Common Stock | 2,300 | $108 | $248.2K | 785,480 |
| 2026-10-06 | Open-market sale | Common Stock | 6,000 | $109 | $656.0K | 779,480 |
| 2026-10-06 | Open-market sale | Common Stock | 9,920 | $110 | $1.1M | 769,560 |
| 2026-10-06 | Open-market sale | Common Stock | 1,780 | $111 | $197.2K | 767,780 |
| 2026-10-07 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-10-07 | Open-market sale | Common Stock | 8,600 | $111 | $954.9K | 779,180 |
| 2026-10-07 | Open-market sale | Common Stock | 10,300 | $112 | $1.2M | 768,880 |
| 2026-10-07 | Open-market sale | Common Stock | 900 | $113 | $101.5K | 767,980 |
| 2026-10-07 | Open-market sale | Common Stock | 200 | $114 | $22.7K | 767,780 |
| 2026-10-08 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-10-08 | Open-market sale | Common Stock | 4,810 | $108 | $520.3K | 782,970 |
| 2026-10-08 | Open-market sale | Common Stock | 3,090 | $109 | $336.5K | 779,880 |
| 2026-10-08 | Open-market sale | Common Stock | 11,900 | $110 | $1.3M | 767,980 |
| 2026-10-08 | Open-market sale | Common Stock | 200 | $111 | $22.1K | 767,780 |
| 2026-10-06 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 61,552 |
| 2026-10-07 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 41,552 |
| 2026-10-08 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 21,552 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Option exercise/conversion (20,000 shares) |
| 2026-10-06 | Open-market sale (2,300 shares) |
| 2026-10-06 | Open-market sale (6,000 shares) |
| 2026-10-06 | Open-market sale (9,920 shares) |
| 2026-10-06 | Open-market sale (1,780 shares) |
| 2026-10-07 | Option exercise/conversion (20,000 shares) |
| 2026-10-07 | Open-market sale (8,600 shares) |
| 2026-10-07 | Open-market sale (10,300 shares) |
| 2026-10-07 | Open-market sale (900 shares) |
| 2026-10-07 | Open-market sale (200 shares) |
| 2026-10-08 | Option exercise/conversion (20,000 shares) |
| 2026-10-08 | Open-market sale (4,810 shares) |
| 2026-10-08 | Open-market sale (3,090 shares) |
| 2026-10-08 | Open-market sale (11,900 shares) |
| 2026-10-08 | Open-market sale (200 shares) |
| 2026-10-06 | Option exercise/conversion (20,000 shares) |
| 2026-10-07 | Option exercise/conversion (20,000 shares) |
| 2026-10-08 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., bearish, Helen Torley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.